ViiV Healthcare
ViiV Healthcare shares data for two-drug regimen for HIV-1 maintenance therapy
July 23, 2024Research and Development GSK, HIV, HIV/AIDS, ViiV Healthcare, maintenance therapy
GSK has announced that ViiV Healthcare, a specialist HIV company predominantly owned by GSK with Pfizer and Shionogi as shareholders, …
ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment
February 21, 2024Research and Development Cabenuva, HIV, HIV/AIDS, ViiV Healthcare, clinical trial, injectables
ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, which assessed Cabenuva (cabotegravir and …
China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment
October 26, 2023Research and Development HIV, HIV/AIDS, NMPA, ViiV Healthcare, Vocabria
ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved Vocabria (cabotegravir injection) used in …
ViiV Healthcare gains positive CHMP opinion for cabotegravir for HIV prevention
July 24, 2023Medical Communications CHMP, EMA, HIV, HIV/AIDS, ViiV Healthcare, cabotegravir
GSK has announced that ViiV Healthcare has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal …
GSK’s ViiV and Halozyme to collaborate on ‘ultra-long acting’ HIV drugs
June 22, 2021Manufacturing and Production GSK, HIV, ViiV Healthcare
ViiV Healthcare, the specialist HIV company majority owned by GlaxoSmithKline (GSK), is to collaborate with Halozyme Therapeutics, giving it exclusive …
ViiV presents positive long-term data for combined HIV treatment
March 8, 2021Sales and Marketing HIV, ViiV Healthcare
ViiV Healthcare has presented positive long-term data from its global Phase IIIb ATLAS-2M study of the first complete, long-acting regimen …
ViiV’s long-acting HIV drug Cabenuva gets FDA approval
January 22, 2021Medical Communications HIV, ViiV Healthcare
The FDA has approved ViiV’s Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in …
ViiV and Chelsea & Westminster Hospital launch digital service for HIV patients
January 18, 2021Sales and Marketing HIV, ViiV Healthcare
Global specialist HIV company ViiV Healthcare and Chelsea and Westminster Hospital NHS Foundation Trust have launched a new service, Klick, …
ViiV’s two-drug regimen proves non-inferior in treatment-naive HIV-1
October 5, 2020Research and Development, Sales and Marketing HIV-1, ViiV Healthcare, pharma
ViiV Healthcare has taken the opportunity at the HIV Glasgow 2020 Virtual Congress to unveil three-year Phase 3 data from …
ViiV Healthcare secures FDA approval for Rukobia combo in multidrug-resistant HIV-1
July 6, 2020Sales and Marketing FDA, HIV, ViiV Healthcare
ViiV Healthcare, the HIV specialist majority owned by GSK which also counts Shionogi and Pfizer among its shareholders, has secured …
Japan welcomes approval of ViiV’s Dovato for HIV-1
January 17, 2020Medical Communications, Sales and Marketing Dovato, Japan, ViiV Healthcare, pharma
Japan’s Ministry of Health, Labour and Welfare (MHLW) has awarded marketing approval to ViiV Healthcare, a subsidiary of GSK, for …
GSK’s two drug HIV regimen effective when administered every two months
August 22, 2019Research and Development AIDS, GSK, HIV, ViiV Healthcare, viral supression
GSK’s long-acting, two-drug HIV regimen was as effective in supressing patient’s viral loads when administered every two months (eight weeks), …
ViiV’s Dovato approved in Europe as treatment option for HIV-1
July 3, 2019Research and Development, Sales and Marketing Dovato, GSK, HIV, ViiV Healthcare, pharma
ViiV Healthcare, the specialist HIV firm majority owned by GSK, is celebrating the news that the European Commission has chosen …
ViiV Healthcares scores first twin-drug FDA approval for untreated HIV-1
April 9, 2019Manufacturing and Production, Research and Development GSK, HIV, ViiV Healthcare, pharma
ViiV Healthcare, the pharmaceutical firm owned by Shionogi, Pfizer and predominantly GSK, has announced its two-drug HIV regimen Dovato (dolutegravir …
Janssen and ViiV’s monthly injectable HIV combo proves non-inferior to daily standard of care
August 15, 2018Research and Development HIV, Janssen, ViiV Healthcare, pharma
Janssen and GSK’s ViiV Healthcare have unveiled strong new Phase 3 data on its two-drug regimen, injected once a month, …
